15, Apr 2026
India’s Fertiliser Dilemma: Self-Reliance Push Signals Policy Reset, but Execution Will Decide Outcomes
New Delhi, April 15 (BNP): India’s fertiliser policy rarely makes headlines, but the recent brainstorming session by the National Academy of Agricultural Sciences signals something more consequential than routine review. It points to a system under strain—and, more importantly, to a policy establishment that seems ready to rethink its foundations.
For decades, fertilisers have been central to India’s agricultural rise. The gains of the Green Revolution were built on assured access to chemical inputs, especially urea. That model delivered food security. But it also locked India into a structure that is now proving costly, inefficient and environmentally fragile.
At the heart of the problem is dependence. India consumes roughly 33 million tonnes of fertilisers annually, yet relies heavily on imports for key nutrients like phosphorus and potassium. Even urea, often seen as domestically secure, is tied to global markets through imported natural gas.
This leaves the country vulnerable to geopolitical shocks and price swings. Recent global disruptions have made that vulnerability hard to ignore. Fertiliser security is no longer a technical concern. It is a strategic one, sitting alongside food and energy security.
The fiscal burden reflects this reality. A subsidy bill of ₹1.71 lakh crore is not just a budgetary line item; it is the cost of sustaining an increasingly inefficient equilibrium.
The bigger issue is not just how much India imports, but how it uses what it imports.
Subsidy structures have long favoured nitrogen, particularly urea, leading to a skewed nutrient balance. Farmers, responding rationally to price signals, overapply nitrogen while underusing other essential nutrients. The result is declining soil health and diminishing productivity gains.
Low nutrient-use efficiency compounds the problem. A significant share of fertilisers never reaches the crop, lost instead to the air, water or soil processes. This raises costs for farmers and creates environmental damage that policy has historically overlooked.
In effect, India is spending more each year to get less out of its soils.
What makes the NAAS discussions noteworthy is not just the diagnosis, but the willingness to consider structural change.
Bringing urea under a nutrient-based subsidy regime would be a major departure from the current system. So would linking subsidies to soil health metrics or moving toward direct benefit transfers. These ideas have circulated before, but rarely with this level of institutional backing.
Together, they suggest a shift from input-centric policy to outcome-oriented policy—where the goal is not just to provide fertilisers, but to ensure they are used efficiently and sustainably.
The push for Integrated Nutrient Supply and Management (INSAM) reinforces this direction. Replacing a quarter of mineral fertilisers with organic alternatives within three years is an ambitious target. More importantly, it reflects a conceptual shift: from dependence on chemical inputs to a more balanced nutrient ecosystem.
Technology is expected to play a central role in this transition. Precision agriculture tools, AI-driven advisories and sensor-based systems could help farmers apply the right nutrients in the right quantities at the right time.
This matters because India’s agricultural extension system has historically emphasised increasing input use rather than optimising it. Digital platforms offer a chance to correct that imbalance by delivering tailored, real-time guidance at scale.
But technology is not a silver bullet. Adoption will depend on affordability, usability and trust—factors that have limited the impact of past innovations.
If the direction is becoming clearer, the path remains uncertain.
Fertiliser reform, particularly around urea, has long been politically sensitive. Any attempt to rationalise subsidies risks immediate resistance from farmers, even if the long-term benefits are clear.
Similarly, scaling organic inputs and bio-fertilisers requires more than policy targets. It demands reliable supply chains, quality assurance and behavioural change at the farm level. Farmers will shift practices only if they see consistent results.
This is where many well-intentioned reforms falter—not in design, but in execution.
What makes this moment different is the convergence of pressures. Fiscal constraints, environmental degradation and global supply risks are all pushing in the same direction. That alignment creates a window for reform that is both rare and time-bound.
The NAAS roadmap does not offer quick fixes. Instead, it outlines a transition—away from a subsidy-heavy, input-driven system toward one that prioritises efficiency, resilience and soil health.
Whether that transition succeeds will depend less on policy announcements and more on coordination: across ministries, between Centre and states, and most critically, with farmers themselves.
India’s next agricultural transformation will not be about producing more at any cost. It will be about producing better, with fewer resources and greater resilience. The fertiliser debate is where that shift is beginning to take shape.
- 0
- By Neel Achary
15, Apr 2026
ITS America Conference & Expo 2026 Launches Cybersecurity & Data Zone in Detroit
DETROIT, Mich. (April 15, 2026) – ITS America Conference & Expo, organized in partnership by RX Global and ITS America, announces the launch of the Cybersecurity & Data Zone at the June 9-12, 2026 event to address the evolving connected industry and the management of data and cybersecurity. The dedicated space within the Huntington Place Exhibit Hall in Detroit will showcase cutting-edge technologies designed to protect connected vehicles, secure smart infrastructure, and strengthen transportation system resilience. The zone brings together cybersecurity tools, data management solutions, and industry experts, offering attendees direct access to technologies shaping secure and reliable intelligent transportation systems.
More than 30 exhibitors focused on Cyber and Digital Security and Data Management and Data Analytics will be part of the event, giving attendees direct access to some of the most recognized names in the field. Among them, Palo Alto Networks brings its AI-driven cybersecurity platforms trusted by more than 70,000 customers worldwide, Flock Safety offers its automated license plate recognition, video surveillance, and other detection systems, and Cisco Systems contributes its globally recognized networking and cybersecurity solutions.
“Cybersecurity is a fundamental requirement for the safe deployment of intelligent transportation technologies that connect our vehicles, infrastructure, and data systems,” said Laura Chace, President and CEO, ITS America. “The Cybersecurity & Data Zone represents our industry’s commitment to safe innovation and demonstrates how we can advance transportation technology while maintaining the highest security standards that protect people and the critical infrastructure they use.”
As transportation systems become more connected, the need to protect them grows just as fast. Cybersecurity threats targeting vehicles, infrastructure, and data networks pose real risks to public safety and system reliability. The Cybersecurity & Data Zone gives transportation professionals a dedicated space to find the tools and expertise needed to stay ahead of those risks.
“Transportation leaders need practical tools and strategies to address cybersecurity challenges while continuing to advance innovation,” said Jaime McAuley, Event Vice President, RX Global. “This zone creates a focused environment where professionals can explore solutions, connect with experts, and develop the knowledge needed to deploy secure transportation technologies that benefit communities nationwide.”
The ITS America Conference & Expo 2026 emphasizes cybersecurity as a core requirement for safety, reliability, and public trust as transportation systems become more digital, connected, and automated. Industry leaders will spotlight these topics to help attendees stay ahead of emerging challenges through cutting-edge solutions, hands-on workshops, and insights. The event provides transportation professionals with comprehensive resources to navigate the complex security landscape facing modern mobility systems.
Cybersecurity & Data Sessions & Events
-
Data Exchange and Its Role in the Larger Digital Infrastructure System
-
From Data to Decisions: AI-Driven Solutions for Modern Transportation
-
Breaking Down Data Silos to Unlock Scalable ITS Solutions
-
Smart Transportation: Digital Infrastructure and Data Integration
-
Workshop: Building Cyber Resilient Transportation Systems
Running June 9-12, 2026, at Huntington Place in Detroit, Michigan, ITS America Conference & Expo connects public and private sector transportation professionals through hands-on demonstrations of technologies, including automated traffic signal performance measures, emergency vehicle preemption systems, connected vehicle integration capabilities, and autonomous mobility solutions. This year’s event operates under the theme “Empowering Innovation” and focuses on how leaders implement and deploy new technology to create safer, smarter, and more connected transportation systems.
See below to explore these innovations and more: https://www.itsamericaevents.
15, Apr 2026
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF)
SOUTH SAN FRANCISCO, Calif., April 15, 2026: CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the third patient in the second cohort (sixth patient overall) in its Phase 1 CER-1236 clinical trial in hematologic malignancies. The patient had MDS that evolved to acute myeloid leukemia (AML). The trial was recently expanded to include earlier forms of MDS and myelofibrosis (MF).
The study continues to progress in accordance with protocol, with patients undergoing monitoring for safety, pharmacokinetics, pharmacodynamics, and clinical activity. With more than seven days of follow-up completed after the most recent infusion, CERo continues to evaluate key endpoints across dose levels as it advances through dose escalation.
As previously presented at the February Tandem Meetings in Salt Lake City, CER-1236 has demonstrated no reported cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade, and no dose-limiting toxicities observed during the 28-day assessment window. Investigators also reported in vivo cell expansion, with peak levels observed between days 10 and 14 following infusion. Additionally, as previously reported, a single patient with inv(3) AML who received four CER-1236 infusions over five months at the lowest dose level achieved 72 consecutive days of platelet transfusion independence. These findings informed the protocol amendment expanding enrollment into patients with MDS and MF.
Robert Sikorski, M.D., Ph.D., CERo Chief Medical Officer, stated, “This is the third patient in the cohort, and completion of the dose-limiting toxicity evaluation period may enable further dose escalation in accordance with the protocol. We continue to evaluate the safety profile and early clinical data as CER-1236 is studied in patient populations with significant unmet need.”
The first-in-human, multi-center, open-label Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236. The trial was initially focused on AML patients, including those with relapsed/refractory disease, measurable residual disease, or newly diagnosed TP53-mutated AML, and has since expanded to include transfusion-dependent MDS (TD-MDS), high-risk MDS (HR-MDS), and post-JAK inhibitor myelofibrosis (MF). Primary endpoints include safety and tolerability, while secondary endpoints include pharmacokinetics and measures of clinical response, including overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD).
CERo Chief Executive Officer Chris Ehrlich added, “Dosing our sixth patient and expanding into MDS represents continued execution of the CERTAIN-T trial and an important milestone for CERo. We believe CER-1236 has the potential to address multiple hematologic malignancies, and we look forward to further advancing the study and sharing additional clinical updates.”
14, Apr 2026
Lightrun’s 2026 State of AI-Powered Engineering Report: Almost Half of AI-Generated Code Fails in Production
Software Failures and Lack of Runtime Visibility Prevent Engineering Teams from Trusting Coding Assistants and AI SREs
NEW YORK, April 14, 2026 — Lightrun, the leader in software reliability, today released its State of AI-Powered Engineering Report 2026, based on an independent poll of 200 SREs and DevOps leaders (Directors, VPs, and C-levels at Enterprises in the US, UK, and EU). The report reveals that, until AI-powered engineering tools have live visibility of how code behaves at runtime, they cannot be trusted to autonomously ensure reliable systems.
Lightrun’s report reveals that a major volume of manual work is required when AI-generated code is deployed: 43% of AI-generated code requires manual debugging in production, even after passing QA or staging tests. Furthermore, an average of three manual redeploy cycles are required to verify a single AI-suggested code fix in production.
As the volume of AI-generated code is rapidly increasing, it is essential to close this verification loop. As a result, engineering teams are turning to AI SRE (site reliability engineering) tools. These agents reason over existing observability, codebase changes, and infrastructure signals to propose incident causes and recommend fixes. However, the report found that 77% of engineering leaders lack confidence in current observability stacks to support automated root cause analyses and remediations.
Lightrun’s report, conducted with independent research firm Global Surveyz, captures the perspectives of senior engineering leaders on the AI-powered SDLC. It explores several timely issues, including:
● AI-Generated Code Reliability Concerns: 88% of companies require 2-3 manual redeploy cycles just to confirm an AI-generated fix actually works in production.
● Wasted Developer Time: Developers spend an average of 38% of their week (two days) on debugging, verification, and troubleshooting.
● The Runtime Visibility Gap: 60% of SRE and DevOps leaders identify a lack of runtime visibility as the primary bottleneck in resolving incidents. This is underscored by the fact that, in 44% of cases where AI SREs or APM tools investigations failed, it was due to the necessary execution-level data not being captured.
● AI SREs: The Trust Wall: 97% of engineering leaders say AI SREs operate without significant visibility into what’s actually happening in production. And, 54% of resolutions to high-severity incidents still use tribal knowledge rather than diagnostic evidence from AI SREs or APMs.
This represents the core challenge of AI-accelerated engineering. Today’s AI agents operate using probability, reasoning their way toward conclusions. To ground that reasoning in reality, the report makes clear they need real-time visibility into what’s happening, including variable states, memory usage, and how requests move through a system.
“Engineering organizations need runtime visibility to embrace the possibilities offered by AI-accelerated engineering. Without this grounding, we aren’t slowed by writing code anymore, but by our inability to trust it,” said Ilan Peleg, CEO of Lightrun. “When almost half of AI-generated changes still need debugging in production, we need to fundamentally rethink how we expect our AI agents to solve complex challenges.”
The report is available online at http://lightrun.com/ebooks/
14, Apr 2026
BIScience Launches the First AI Suite for Effortless Cross-Media Ad Intelligence
The AdClarity AI Suite combines an AI-powered chatbot that acts as a personal data science expert with proactive AI Insights, covering up to 85% of analyst work in seconds across digital, CTV, and linear TV channels.
New York, NY, April 14, 2026 – BIScience, the company behind AdClarity, the cross-media ad intelligence platform serving more than 2,000 brands including Adidas, Amazon, Booking.com, Disney, Shell, Sony, and Wix, today launches the AdClarity AI Suite. BIScience is the first ad intelligence provider to introduce these capabilities, making competitive insights effortless and accessible to every team member.
The launch represents a fundamental change in methodology, not just a new feature. Until now, ad intelligence platforms have operated as static data repositories, requiring companies to spend significant time, money, and manual effort building reports. BIScience has redesigned this workflow entirely: instead of requiring users to find answers in data, the AI Suite delivers answers and intelligence directly to them across digital display, social, online video, CTV, and linear TV channels.
The suite offers two complementary sides of a single solution. One side helps users clearly define what they need and get precise answers on demand. The other guides them forward, proactively uncovering what matters even when they are not sure where to start, since many teams do not even know which questions they should be asking.
AdClarity AI Chatbot functions as a personal data science expert. Users type questions in natural language and receive structured answers in seconds, drawn exclusively from AdClarity’s own cross-media data. A user can ask “Who’s winning in CTV in 2026 in the US?” or “How did my competitor’s channel mix shift last quarter?” and receive a clear response with key findings, detailed analysis, and supporting tables and charts. Users can drill deeper with follow-up questions and export executive-ready summaries directly from the interface.
AI Insights takes a complementary approach, proactively surfacing important findings inside Brand Reports and key widgets. Rather than waiting for a user to ask the right question, AI Insights automatically generates clear narratives explaining what changed in the competitive landscape and why, updating as users change filters and selections.
“The AdClarity AI Suite represents a fundamental shift in how teams interact with market intelligence,” said Dorit Kaplan, VP of Product and Strategy at BIScience. “By embedding an AI data science layer directly into the platform, we’ve automated the heavy lifting of complex analysis. What used to require hours of manual work is now delivered in seconds, effectively handling 85% of the analytical pipeline instantly. With AI Insights, we’re moving beyond reactive searching to a proactive model that surfaces critical trends before they even appear on a team’s radar.”
Both capabilities operate entirely within the AdClarity platform and draw on BIScience’s full ad intelligence dataset, covering $393 billion in annual ad spend across 52 markets. To learn more or request a demo, visit: https://adclarity.com
14, Apr 2026
Epson to Emphasise ROIC and Seek Sustained Growth by Redesigning Its Business Portfolio and Focusing Resources on Growth Domains
Epson introduces the ENGINEERED FUTURE 2035 Long-Term Corporate Vision and Mid-Term Business Plan, Phase 1
SYDNEY, Apr 14 – Epson has unveiled ENGINEERED FUTURE 2035, a Long-Term Corporate Vision that maps out the company’s strategy to 2035, along with a new Mid-Term Business Plan (2026-2028) that represents the first phase of work under the vision. In line with this plan, Epson will use ROIC as a management metric to optimise capital allocation, redesign its business portfolio, and focus resources on strategic growth domains. By transforming the earnings base and leveraging its precision technologies to expand in growth domains, the company aims to sustain corporate value growth.
Long-Term Corporate Vision ENGINEERED FUTURE 2035
Refining our technologies, engineering the future and delivering real-world value
Epson sees the next decade as one in which volatility is the norm. Environmental and geopolitical risks will rapidly change, resources and energy will be increasingly constrained, and demographic changes will result in labour shortages worldwide. In developed economies, the labour pool continues to shrink. Meanwhile, emerging economies face critical challenges to develop foundational capabilities such as skills, education and infrastructure.
Under these conditions, the sustainability of society and industry will increasingly depend on how effectively Epson can use limited resources, energy, and human potential. It is not enough to evolve technology itself. Driving advances in the technology itself will not be enough. The ability to design and optimise technology so that it genuinely functions within society is becoming increasingly critical. It is precisely because of the many constraints that Epson believes the future should not be left to chance but must be methodically engineered, starting with technology that is conceived in the field and continuously refined and implemented in the real world.
That is why Epson seeks to leverage the efficient, compact, and precise technologies and philosophy it has developed over more than eight decades, building on the foundation of “Sho-Sho-Sei,” to create value that supports the transformation of society and industry through real-world implementation. The essence of Epson lies not in advancing technology for its own sake, but in translating advanced technology into things that are genuinely useful in the real world. Engineering is the force that connects the philosophy of efficient, compact and precise innovation to meaningful social implementation.
Epson will deliver new value to the world by combining its efficient, compact, and precise technologies with designs optimised for real-world uses. From industry and across learning, working, and living, Epson will enhance productivity and reliability and expand the world’s possibilities. So that people and the planet can continue to advance together, Epson will simultaneously raise both social value and corporate value. That is the future that Epson envisions in ENGINEERED FUTURE 2035.
Mid-Term Business Plan, Phase 1 (2026-2028)
Achieving both growth and capital efficiency by optimising capital allocation based on disciplined ROIC management
Epson’s Mid-Term Management Plan, Phase 1 (2026-2028), is the first stage of the company’s journey toward realising the ENGINEERED FUTURE 2035 long-term vision.
Until now, Epson’s business structure has been highly dependent on mature markets, presenting challenges in terms of resource allocation to growth areas, execution speed, and capital efficiency. In Phase 1, Epson will confront these challenges head-on, transforming the earnings base and focusing resource allocation on growth domains. Management will emphasise capital efficiency, using ROIC as the primary management metric. By exercising disciplined ROIC-based management, Epson will aim to achieve a ROIC of 8% by fiscal 2028 and to build a solid foundation for sustainable growth.
Specifically, Epson will review its fixed cost structure and asset efficiency, redesign global operations and the supply chain, and strengthen sales in emerging markets. It will simultaneously expand and enhance recurring business and solutions. These efforts will enable Epson to reduce invested capital while enhancing the earning power of its businesses. At the same time, the company will prioritise the allocation of the cash generated to future growth domains, accelerating the transformation of its business portfolio. Capital will be optimally allocated, with investment and business decisions made based on disciplined ROIC.
Cash created through this transformation of the earnings base will be actively deployed, under disciplined capital allocation, to projects that maximise long-term value creation. In addition to strategic investments in things such as mergers and acquisitions, Epson will invest a total of ¥280 billion over the three-year period in growth domains, including in the Precision Innovation segment as the primary growth engine and the Industrial & Robotics segment, which will be a key growth driver for the next phase.
Throughout the period of the mid-term business plan, Epson will reinforce its management discipline and execution capabilities to sustain growth and increase corporate value, while driving structural transformation toward 2035.
14, Apr 2026
Ransomware Attacks Surge in India; Manufacturing Firms Among Most Affected: Report
Apr 14 (BNP): India has emerged as a major target for cybercriminals, becoming the Asia-Pacific hotspot for ransomware attacks, with the manufacturing sector among the worst affected, according to a recent industry report.
The study highlights that a significant share of impacted organisations in India’s manufacturing sector were forced to pay ransom demands in 2025, underscoring the growing financial and operational risks posed by cyberattacks.
Experts note that ransomware groups are increasingly targeting industrial operations, where disruptions can halt production, impact supply chains, and cause large-scale financial losses.
The report also points to a rising trend of extortion-based attacks, where data is stolen and companies are pressured into paying to prevent its release or to restore access.
India’s rapid digitalisation and expanding industrial base have made it an attractive target for global cybercriminal networks, particularly those focusing on high-value sectors like manufacturing.
Security experts warn that unless organisations strengthen cyber defences and invest in advanced threat detection systems, such attacks are likely to continue rising in frequency and severity.
14, Apr 2026
The End of Knee Replacement? Regenerative Medicine Offers New Promise
Punjab , 14 April 2026 :
In homes across India, knee pain is often accepted as an inevitable part of ageing. It begins quietly—difficulty climbing stairs, discomfort while sitting or standing—but gradually starts limiting mobility and independence. For decades, the treatment pathway has remained largely unchanged: when medicines, physiotherapy, and injections fail, knee replacement becomes the next step. But what if that approach needs rethinking?
Dr. N.K. Aggarwal, a veteran orthopaedic surgeon with over 50 years of experience and among the early pioneers of knee replacement surgery in India, once firmly believed in that solution. Having trained and worked at leading centres in India, the UK, Europe, and the United States, and served as Professor and Head of Orthopaedics at Christian Medical College, Ludhiana, he has performed thousands of procedures over his career. His patients often regained mobility. Yet, over time, a concern began to take shape.
After 15–20 years of performing knee replacements, Dr. Aggarwal observed a pattern that many surgeons worldwide were also beginning to acknowledge. Even when surgeries were technically successful—with complication rates below 5%—nearly 20–25% of patients remained dissatisfied. Pain persisted, stiffness lingered, and mobility did not fully return to expectations. Technological advancements such as robotics and computer navigation improved surgical precision, but they did not significantly improve patient satisfaction. The question became difficult to ignore: were surgeons addressing the disease itself, or only its most visible outcome?
A Personal Turning Point
The shift in perspective was not driven by research alone, but by personal experience. Around a decade ago, Dr. Aggarwal’s wife, herself a doctor, began suffering from severe knee pain. Her condition worsened to the point where walking became difficult, and travel required the use of a wheelchair. Like many patients, she was advised knee replacement by leading specialists.
However, Dr. Aggarwal hesitated. His years of clinical experience had shown him that even a technically successful surgery did not always guarantee a satisfactory outcome. This moment prompted him to look beyond conventional solutions and re-examine the underlying causes of knee pain.
A deeper exploration of global research led to a crucial insight: knee osteoarthritis is not merely a result of mechanical wear and tear. Increasingly, it is understood as part of a chronic, low-grade inflammatory process associated with ageing—often referred to as “inflammaging.” This gradual inflammation affects not just the cartilage, but also ligaments, muscles, and surrounding tissues.
In this context, knee pain is not just a localised joint issue, but a manifestation of a broader systemic condition. Treating only the joint, therefore, may not address the root cause of the problem.
The Shift to Regeneration & Birth of the Ludhiana Protocol
Building on this understanding, Dr. Aggarwal began integrating a range of established, non-surgical treatments that had previously been used in isolation. These included joint lavage (cleaning of the joint), lubrication therapies, platelet-rich plasma (PRP) and growth factor-based treatments derived from the patient’s own blood, as well as orthobiologic interventions using fat or bone marrow.
Alongside these, he incorporated systemic measures aimed at reducing overall inflammation through medication, supplements, and lifestyle modifications.
This integrated approach, known as the Ludhiana Protocol, focuses on reducing inflammation, improving the joint environment, and supporting the body’s natural healing processes—shifting the emphasis from replacement to regeneration.
His wife was among the first to undergo this treatment and experienced significant improvement over time. Encouraged by these results, Dr. Aggarwal extended the approach to other patients. Since then, hundreds have been treated, with over 95% reporting improvement in pain and mobility. Many who had been advised knee replacement are now managing without surgery.
The procedure itself is minimally invasive. It typically does not require hospital admission, major anaesthesia, or prolonged bed rest. Patients are often able to walk in and walk out on the same day.
Not a Miracle, But a Realistic Path Forward
While the results are promising, Dr. Aggarwal emphasises that regenerative treatment is not a universal substitute for surgery. In advanced cases, particularly where the knee is severely deformed, replacement may still be necessary. However, in early to moderate stages, timely intervention can help delay or even avoid surgery.
Improvement is gradual rather than immediate—patients may notice changes within weeks, with more significant benefits developing over two to three months.
A Growing Public Health Concern
Knee osteoarthritis is a significant and growing health concern in India. Studies indicate a high prevalence among individuals aged 60 and above, with women more commonly affected. Sedentary lifestyles, obesity, and longer life expectancy are contributing to an increasing number of cases, even among younger populations.
In this context, approaches that focus on early intervention and preservation of natural joints may play an important role in reducing long-term burden.
Dr. Aggarwal’s journey reflects a broader transition in orthopaedic care—from replacing damaged joints to understanding and treating the underlying disease.
Now based at the N.K. Aggarwal Joints & Spine Centre in Ludhiana, he continues to advocate for early diagnosis and informed decision-making. As he puts it, “We cannot stop ageing, but we can control its painful effects on the knees. The earlier we begin treatment, the better the chances of preserving the natural joint.”
He still performs knee replacement, when necessary, but considers it a last resort rather than the first line of treatment.
For patients, the message is clear: knee pain should not be ignored, nor should surgery be the only option considered. With evolving medical understanding, a more balanced and patient-centric approach is now emerging—one that prioritises preservation, function, and long-term quality of life.
14, Apr 2026
Amit Shah Calls Women’s Reservation Bill Urgent Step for Political Empowerment
New Delhi, Apr 14 (BNP): Union Home Minister Amit Shah on Tuesday said the Women’s Reservation Bill is a crucial and timely reform, stressing the need for its swift implementation.
In a post on social media platform X, Shah highlighted that the bill is aimed at strengthening women’s participation in policymaking and ensuring greater representation of “Nari Shakti” in governance.
He described the proposal as an important step toward empowering women and said it reflects a broader commitment to inclusive decision-making in the country.
Shah further stated that the reform should be implemented without delay, calling it essential for enhancing democratic participation.
The Women’s Reservation Bill is widely viewed as a significant initiative to improve gender balance in legislative bodies and increase women’s role in political leadership.
14, Apr 2026
Rising Heat in Kerala Triggers Government Advisory
Apr 14 (BNP): Kerala has issued a heat alert as temperatures are expected to rise sharply in the coming days across several districts.
Chief Minister Pinarayi Vijayan warned that Palakkad may record temperatures close to 40°C, while Kollam could reach around 39°C. Most other regions are likely to experience temperatures between 36°C and 37°C.
The State Disaster Management Authority has advised residents to take precautions, especially during peak afternoon hours. People have been urged to avoid direct sunlight between 10 am and 3 pm, stay hydrated, and take necessary steps to prevent heat-related illnesses such as sunstroke.
Authorities have also asked vulnerable groups, including children, elderly citizens, and outdoor workers, to remain cautious during the intense heat conditions.
The advisory comes amid a steady rise in summer temperatures across the state, signalling a continuing heatwave-like situation in several parts of Kerala.
